Cdc6 and Cyclin E2 Are PTEN-Regulated Genes Associated with Human Prostate Cancer Metastasis  by Wu, Zhong et al.




Zhong Wu*, HyungJun Cho†, Garret M. Hampton‡
and Dan Theodorescu*,§
*Department of Molecular Physiology and Biological
Physics, University of Virginia, Charlottesville, VA, USA;
†Departments of Statistics and Biostatistics, Korea
University, Seoul, South Korea; ‡Department of
Biochemistry and Biomarker Development, Celgene Corp.,
San Diego, CA, USA; §Paul Mellon Urologic Cancer Institute,
University of Virginia, Charlottesville, VA, USA
Abstract
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is frequently inactivated in metastatic pros-
tate cancer, yet the molecular consequences of this and their association with the metastatic phenotype are in-
completely understood. We performed transcriptomic analysis and identified genes altered by conditional PTEN
reexpression in C4-2, a human metastatic prostate cancer cell line with inactive PTEN. PTEN-regulated genes were
disproportionately represented among genes altered in human prostate cancer progression and metastasis but not
among those associated with tumorigenesis. From the former set, we identified two novel putative PTEN targets,
cdc6 and cyclin E2, which were overexpressed in metastatic human prostate cancer and up-regulated as a func-
tion of PTEN depletion in poorly metastatic DU145 human prostate cancer cells harboring a wild type PTEN. Inhi-
bition of cdc6 and cyclin E2 levels as a consequence of PTEN expression was associated with cell cycle G1 arrest,
whereas use of PTEN activity mutants revealed that regulation of these genes was dependent on PTEN lipid phos-
phatase activity. Computational and promoter-reporter evaluations implicated the E2F transcription factor in PTEN
regulation of cdc6 and cyclin E2 expression. Our results suggest a hypothetical model whereby PTEN loss up-
regulates cell cycle genes such as cdc6 and cyclin E2 that in turn promote metastatic colonization at distant sites.
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Introduction
Various mechanisms contribute to prostate cancer progression to ad-
vanced stage [1,2]. Among them, the deletion of tumor suppressor
gene PTEN (phosphatase and tensin homolog deleted on chromo-
some 10) is a frequent molecular alteration associated with tumor
progression [3,4]. Although only approximately 30% of primary
prostate cancers have PTEN mutations, these are found in up to
60% of metastatic and advanced prostate cancers [5,6]. PTEN dele-
tion is also correlated with a high Gleason score and advanced tumor
stage [7]. Although the correlation between loss of PTEN activity
and prostate cancer progression is clear, the effectors responsible
for this association remain incompletely characterized.
Genome-wide expression analysis of human tumors has demon-
strated that models, which predict clinical outcome in patients, can
be constructed [8]. Gene expression signatures can also be identified,
which reflect the activation status of oncogenic pathways, and these
in turn provide clinically relevant associations with disease outcomes
[9]. Recently, a microarray gene expression signature for immunohisto-
chemistry (IHC)-detectable PTEN loss in breast cancer has been devel-
oped [10]. Importantly, some PTEN IHC-positive cancers exhibited
the signature of PTEN loss, suggesting that the signature is more sensi-
tive than PTEN IHC for identifying tumors with pathway activation.
Furthermore, this signature correlated to poor patient outcome in inde-
pendent data sets of breast, bladder, and prostate carcinoma.
With the objective of determining effectors of PTEN that are re-
lated to prostate cancer metastasis, here we use a conditional PTEN re-
expression model [11] to develop gene expression signatures associated
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with PTEN. To identify PTEN-regulated genes important in prostate
cancer progression and metastasis, we focused on transcripts whose ex-
pression was altered as function of human prostate cancer metastasis.
Using this approach, we identified cdc6 and cyclin E2 as novel PTEN-
regulated targets associated with prostate cancer metastasis.
Materials and Methods
Reagents
Akt inhibitor, 1,3-dihydro-1-(1-((4-(6-phenyl-1H -imidazo[4,5-g]
quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H -benzimidazol-2-
one (Akt inhibitor VIII), and JNK inhibitor, anthra[1,9-cd]pyrazol-6
(2H )-one (SP600125), were purchased from EMD Chemicals (San
Diego, CA).
Transcriptional Analysis of pTetOn PTEN C4-2 Cells
pTetOn PTEN C4-2 prostate cancer cells in which expression of
PTEN is under the control of TetOn system were previously described
[11]. Cells were treated with 1 μg/ml doxycycline (DOX) or vehicle for
24 hours and then total RNA were isolated and hybridized to HG-
U133A GeneChip Array (Affymetrix, Santa Clara, CA) as described
[12]. Cells used for transcriptional profiling were concurrently evalu-
ated by Western blot to confirm expression of the PTEN transgene as
described [11]. This experiment was repeated with a completely differ-
ent batch of cells 1 week after the initial experiment to provide dupli-
cate samples for statistical analysis. The local pooled error (LPE) test
[13] was used to find differentially altered probe sets in response to
DOX treatment (PTEN expression). Probe sets with a false discovery
rates (FDRs) of <.01 were designated as regulated by PTEN.
Unsupervised Cluster Analysis of Probe Sets Altered by PTEN
Expression as Compared to Probe Sets in Human Prostate
Cancer Tumors
Using RMA [14] implemented in the Bioconductor project (http://
www.bioconductor.org/), we computed expression measures from
PTEN and human prostate tumor microarray data [15]. Details of hu-
man tumor samples were described before [15]. Log2 transformation
and interquartile range normalization were carried out for both data
sets. Because these two sets were hybridized to different platforms
(U133Plus2 for human tumor set and U133A for PTEN/cell lines
set), we compared UniGene IDs between these two data sets and se-
lected only probe sets in the human data that matched those identified
as PTEN-regulated in the analysis described above. Hierarchical clus-
tering analysis was performed on the human data with those selected
probe sets because it clusters coexpressed genes and shows expression
patterns of gene clusters effectively. Thus, all the probe sets that were
clustered on the human data were also specifically regulated by PTEN
expression with statistical significance based on the LPE test.
To further explore the correlation of PTEN-regulated probe sets
with those altered as a function of prostate cancer metastasis, the num-
ber of probe sets that were differentially regulated by PTEN was re-
duced by examining the differential expression of correlated probe
sets in the human data set between metastatic and nonmetastatic sam-
ples. Using the two-sample t tests, we examined the statistical signifi-
cance between benign and localized samples and the significance
between localized and metastatic samples. After computing Benjamini
and Hochberg–adjusted P values [16] from the raw P values of the
two-sample t tests using the multitest package of the Bioconductor
project because of the multiple testing, we selected probe sets that
met both criteria, adjusted P values >.05 (no statistical difference) be-
tween the benign and localized samples and the adjusted P values <.05
(statistical different) between the localized and metastatic samples. In
other words, the expression levels of those selected probes are statisti-
cally different between localized and metastatic samples, whereas their
expression levels were similar between benign and localized samples.
Hierarchical clustering analysis was performed on this subset of probe
sets as described above.
Promoter Analysis and Interaction Network Toolset Analysis
To find putative transcription factors associated with gene expres-
sion changes altered by PTEN expression, we used the Promoter
Analysis and Interaction Network Toolset (PAINT) [17] (http://
www.dbi.tju.edu/dbi/tools/paint/). This tool identifies and quanti-
tates overrepresentation of transcription factor binding sites in the
promoters of PTEN-regulated gene sets. Gene accession numbers
corresponding to statistically significant (FDR < .01) PTEN-regulated
probe sets were uploaded into PAINT. TRANSFAC Public database
was chosen to find transcriptional regulatory elements (TREs) on up-
stream gene sequences. Enriched TREs were identified by comparing
promoter regions of genes down-regulated by PTEN to all human pro-
moter sequences in the PAINT database.
Real-time Reverse Transcription–Polymerase Chain
Reaction Analysis of Cdc6 and Cyclin E2 Expression Levels
After PTEN Reexpression
Real-time reverse transcription–polymerase chain reaction (RT-PCR)
was carried out on iCycler Optical Module (Bio-Rad, Hercules, CA)
with IQ SYBR Green (Bio-Rad) fluorescent dye included in the PCR
to determine the amount of mRNA level for cdc6 and cyclin E2. Primers
used for cdc6 were forward, 5′-GAGATGTTCGCAAAGCACTG-3′,
and reverse, 5′-TGGGAATCAGAGGCTCAGA-3′. Primers for cyclin
E2 were forward, 5′-CTATTTGGCTATGCTGGAGG-3′, and re-
verse, 5′-TCTTCGGTGGTGTCATAATG-3′. Real-time RT-PCR
for glucuronidase-β was used as an internal control, and primers were
forward, 5′-CCGACTTCTCTGACAACCGACG-3′ and reverse, 5′-
AGCCGACAAAATGCCGCAGACG-3′. Expression levels of cdc6
and cyclin E2 were normalized to the expression of glucuronidase-β
in each sample.
Small Interfering RNA
PTEN small interfering RNA (siRNA) duplex was described pre-
viously [18] and was purchased from Dharmacon (Lafayette, CO)
with the following target sequence: 5′-CCAGUCAGAGGCGCUAU-
GU-3′. siRNA duplex targeting luciferase (GL2), 5′-CGTACGCG-
GAATACTTCGA-3′ was used as control siRNA. Transfection of
DU145 human prostate cancer cells (American Type Culture Col-
lection, Manassas, VA) with siRNA duplexes (200 nM) was done
in six-well plates using OligofectAMINE (Invitrogen, Carlsbad, CA)
according to manufacturer’s instructions.
Cell Cycle Analysis
Cells were trypsinized, and cell cycle analysis with FACSCalibur
was carried out [11]. All flow cytometric measurements were done
using the same instrument settings, and >10,000 cells were analyzed
in each sample. The percentage of cells in different stages of the cell
cycle was determined with ModFit LT3.1 software (Verity Software
House, Topsham, ME).
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DNA Constructs, Transient Transfection, and Luciferase
Reporter Assay
Wild type and E2F binding site–mutated cdc6 promoter frag-
ments in pGL3 basic were gifts from Dr. R.S. Williams [19]. The
E2F luciferase reporter construct was a gift from Dr. S. Chellappan
at University of South Florida. DNA transfection was performed us-
ing lipofectin according to the manufacturer’s protocol (Invitrogen),
and the transfection efficiency was approximately 70% as examined
under the fluorescence microscope with a cotransfected green fluores-
cent protein expression construct. pTetOn PTEN C4-2 cells were
transfected, and 24 hours later, 1 μg/ml DOX was added followed
by an additional 24 hours of incubation. Cells were lysed and ana-
lyzed for luciferase activity according to the manufacturer’s protocol
(Promega, Madison, WI). Luciferase activity was corrected for cell
number with SYBRGold assay (Invitrogen).
Western Blot Analysis
Western blot was carried out as described [11] using anti-HA
monoclonal antibody (Covance, Berkeley, CA) at a 1:3000 dilution.
The monoclonal anti-cdc6 antibody was from Santa Cruz Biotech-
nology (Santa Cruz, CA) and used at a 1:1000 dilution. The poly-
clonal anti–phospho-Akt (Ser473), anti-Akt, anti–phospho-c-Jun,
anti–phospho-Rb, anti–E2F-1, anti-PTEN, and anti–cyclin E2 anti-
bodies were from New England Biolabs (Beverly, MA) and used at a
1:1000 dilution. The monoclonal anti–α-tubulin antibody was pur-
chased from Oncogene (San Diego, CA) and was diluted at 1:2000.
TheHRP-conjugated antimouse (Pierce Biotechnology, Rockford, IL)
or antirabbit (New England Biolabs) secondary antibody was used at
a 1:200,000 dilution.
Results
Transcriptional Profiling of pTetOn PTEN(wt) C4-2 as a
Function of PTEN Reexpression
Transcriptional profiling was carried out as a function of PTEN re-
expression in pTetOn PTENC4-2 prostate cancer cells [11] (Figure 1).
A decrease in phospho-Akt level with the PTEN induction in the C4-2
cells used in profiling was observed, confirming the biochemical im-
pact of the induction. Using the LPE test, we found that 123 probe
sets were differentially altered by PTEN expression with an FDR
P value <.01. Among those 123 probe sets, 88 were up-regulated after
PTEN expression, whereas 35 were down-regulated. The top 10 up-
and down-regulated probe sets and corresponding genes are listed
in Table 1.
Probe Sets Altered by PTEN Expression Preferentially Cluster
with Metastatic Disease in Patients
Because functional loss of PTEN correlates with tumor grade and
stage in prostate cancer, we sought to examine whether probe sets al-
tered in response to PTEN reexpression were related to human pros-
tate cancer progression and metastasis. To do this, we matched our
PTEN-regulated probe sets to probe sets in a human prostate tumor
array set [15] by comparing UniGene IDs because the two array data
used different platforms. A total of 388 probe sets in the human tumor
Figure 1. Flow chart of experimental strategy. Gene expression changes in response to PTEN expression were analyzed by Affymetrix
GeneChip in pTetOn PTEN C4-2 cells after DOX treatment to reexpress PTEN. Probe sets specifically altered by PTEN were identified,
and probe sets in human prostate cancer array data corresponding to PTEN-altered probe sets in C4-2 cells were determined by UniGene
IDs. These PTEN-regulated probe sets in human samples were used for hierarchical clustering analysis with human tumor array data. A
subset of probes was identified as a function of their altered expression in metastasis but not transformation using a two-sample t test.
PTEN target genes, cdc6 and cyclin E2, were further characterized from this subset of probe sets. Western blot confirmed PTEN ex-
pression in samples that were identical to those used in Affymetrix chip analysis. Two separate experiments with different batch of cells
were evaluated.
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data set were found to correspond to the 123 (88 up- and 35 down-
regulated) PTEN-responsive probe sets, respectively. Of the 388, 292
matched to the 88 and 96 to the 35 probe sets in the pTetOn PTEN
C4-2 cells. Unsupervised hierarchical clustering of the 388 probe sets
was carried out in the human tissue data set to determine how PTEN-
regulated genes were associated to prostate cancer stage. Figure 2, A
and B, shows a striking pattern of clustering associated with the tran-
sition between localized and metastatic human cancer rather than be-
tween benign and malignant disease. This was true for both up- and
down-regulated probe sets.
Identification of Probe Sets Altered by PTEN Expression and
Associated with Prostate Cancer Metastasis
The data previously mentioned suggest that probes differentially
expressed as a function of PTEN expression were more likely to be
associated with tumor progression than transformation. To identify
candidate metastasis genes (promoters or suppressors) that are regu-
lated by PTEN, we applied a two-sample t test on the expression
level of each probe identified above in three types of samples (benign,
localized, and metastatic) of the human prostate tissue data. Subsets
of PTEN-altered probe sets and corresponding genes (up- and down-
regulated) were thus identified as differentially expressed between
localized and metastatic samples (P < .05), whereas their expression
levels were not altered between benign and localized samples (P >
.05). To evaluate the effectiveness of this approach, a hierarchical
clustering analysis was applied to these subsets of PTEN-altered
probes on the human tumor data. As shown in Figure 2, C and
D, the clustering pattern of these probe sets even more profoundly
distinguished metastatic samples from benign and localized samples
than before selection (Figure 2, A and B).
PTEN Inhibits the Expression of Cdc6 and Cyclin E2, Two
Genes Up-regulated in Prostate Cancer Metastasis
For further study, we selected genes that were both among the top
10 PTEN-regulated probe sets and altered as a function of human
prostate cancer metastasis. Only two PTEN down-regulated probe
sets met this criterion, corresponding to cdc6 and cyclin E2. Exami-
nation of the human prostate cancer array data [15] showed higher
expression levels of all cdc6 and cyclin E2 probe sets in metastatic
samples compared to benign and localized samples (Figure 3, A
and B). Elevated expression levels of cdc6 and cyclin E2 in metastatic
samples were further supported by results of independent analysis us-
ing Oncomine (Figure 3, C and D) [20].
To validate our microarray data, we used real-time RT-PCR to ex-
amine expression levels of cdc6 and cyclin E2 in response to PTEN
induction and found that their expression levels were inhibited ap-
proximately four- and three-fold, respectively (Figure 4A), confirm-
ing the PTEN chip result. Consistent with mRNA levels, the protein
levels of cdc6 and cyclin E2 were also decreased by three- and two-
fold, respectively, after PTEN expression as indicated by Western
blots (Figure 4B). Real-time RT-PCR was also carried out on pTetOn
C4-2 cells that lacked pTRE2-PTEN vector exposed to DOX. No
significant change of cdc6 and cyclin E2 expression levels was ob-
served in these cells (data not shown), indicating that the inhibition
of cdc6 and cyclin E2 expression was specific to PTEN induction. To
independently verify the regulatory effect of endogenous PTEN on
these two genes, we depleted this protein in DU145, a poorly meta-
static human prostate cell line with high PTEN expression levels
[11]. In support of PTEN regulation of cdc6 and cyclin E2 expres-
sion, depletion of this former protein (Figure 4C ) increased the ex-
pression of the latter two (Figure 4D).
Inhibition of Cdc6 and Cyclin E2 Expression After PTEN
Induction Correlated with a Cell Cycle G1 Block
Both cdc6 and cyclin E2 are implicated in the cell cycle G1- to S-
phase transition [19,21], and our previous work showed that PTEN
expression blocked C4-2 cells at the G1 phase [11]. We began evalu-
ating the relationship of PTEN to cdc6 and cyclin E2 by examining
the correlation of cdc6 and cyclin E2 expression with cell cycle G1
arrest after PTEN reexpression. Minor expression of PTEN was
Table 1. Top Up- or Down-regulated Genes After PTEN Expression in pTetOn PTEN C4-2 Prostate Cancer Cells.
Probe Set* Gene Name Fold Difference†
PTEN up-regulated genes
213350_at Ribosomal protein S11 4.237
201427_s_at selenoprotein P, plasma, 1 3.462
209815_at patched homolog (Drosophila) 2.468
213736_at Cytochrome c oxidase subunit Vb 2.248
202028_s_at ribosomal protein L38 2.177
212952_at Transcribed locus 2.003
217989_at Hydroxysteroid (17-beta) dehydrogenase 11 1.938
204663_at malic enzyme 3, NADP(+)-dependent, mitochondrial 1.899
202627_s_at serpin peptidase inhibitor, clade E, member 1 1.899
213110_s_at collagen, type IV, alpha 5 (Alport syndrome) 1.866
PTEN down-regulated genes
201490_s_at peptidylprolyl isomerase F (cyclophilin F) −2.055
211450_s_at mutS homolog 6 (Escherichia coli) −1.990
220651_s_at MCM10 minichromosome maintenance deficient 10 (Saccharomyces cerevisiae) −1.896
213872_at Chromosome 6 open reading frame 62 −1.857
214079_at dehydrogenase/reductase (SDR family) member 2 −1.850
203968_s_at CDC6 cell division cycle 6 homolog (S. cerevisiae) −1.843
211814_s_at cyclin E2 −1.715
206752_s_at DNA fragmentation factor, 40 kDa, beta polypeptide (caspase-activated DNase) −1.696
209572_s_at embryonic ectoderm development −1.663
217294_s_at enolase 1 (alpha) −1.660
*Affymetrix (www.Affymetrix.com).
†Fold change comparing PTEN-expressing cells (DOX-treated) with PTEN-unexpressed cells (DMSO-treated).
Neoplasia Vol. 11, No. 1, 2009 PTEN Regulated Genes in Prostate Cancer Metastasis Wu et al. 69
observed after 12 hours of treatment with DOX, and its expression
reached maximal after 24 hours of DOX treatment (Figure 5A). Sig-
nificant cell cycle G1 arrest was not observed until 24 hours of treat-
ment with DOX, with the percentage of cells at the G1-phase
increasing from 54% to 75% (Figure 5B). The expression levels of
cyclin E2 and cdc6 were significantly inhibited after 12 hours of
treatment with DOX, and both expression levels were maximally re-
duced at 24 hours of DOX treatment (Figure 5C ). The correlated
cell cycle G1 block with reduced expression of cyclin E2 and cdc6
after PTEN expression suggests that the cell cycle G1 arrest after
PTEN expression in C4-2 cells may be associated with PTEN inhi-
bition in cyclin E2 and cdc6 expression.
Figure 2. (A–B) Unsupervised cluster analysis of all probe sets regulated by PTEN in C4-2 cells, which matched with those in human
prostate tumor array data. Probe sets that are specifically regulated by PTEN in our pTetOn PTEN C4-2 chip analysis were identified and
linked to probe sets in human tumor array data based on their UniGene IDs. A total of 292 (A) and 96 (B) probe sets in human array data
were found to be corresponding to 88 up- and 35 down-regulated PTEN-responsive probe sets, respectively. These 96 and 292 probe
sets were used in an unsupervised hierarchical cluster analysis with human tumor array data, and heat maps were generated to show
the expression patterns of these probe sets among the three sample sets (benign, localized, and metastatic) of prostate cancer tissues.
(C–D) Cluster analysis of a subset of PTEN-regulated probe sets as a function of prostate cancer metastasis. The number of probe sets
(388 total) in human tumor array data that were corresponding to PTEN-regulated probes were reduced by a two-sample t test: adjusted
P> .05 (no statistical difference) between the benign and localized samples and the adjusted P< .05 (statistically different) between the
localized and metastatic samples. The resulting 61 up- (C) and 21 down-regulated (D) PTEN-responsive probe sets were clustered with
human tumor array data, and the expression patterns of these probe sets among human prostate tumor samples (benign, localized, and
metastatic) were shown with corresponding heat maps.
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Lipid Phosphatase Activity Is Required for PTEN Inhibition of
Cdc6 and Cyclin E2 Expression
PTEN has both lipid and protein phosphatase activity, and its lipid
phosphatase activity has been associated with its growth inhibitory ef-
fect. Because inhibition of cdc6 and cyclin E2 by PTENwas implicated
in PTEN cell cycle G1 arrest, we sought to determine whether its lipid
phosphatase activity is involved in its inhibition of cdc6 and cyclin E2
expression levels by examining expression levels of these two genes
after the induction of G129E mutant PTEN that lacked lipid phospha-
tase activity in C4-2 (Figure 6A) [11]. In contrast to wild type PTEN,
expression of G129E mutant PTEN had no effect on cdc6 and cyclin
E2 expression levels (Figure 6, B and C ). Consistently, no significant
change of cell cycle distribution was observed after G129E mutant
PTEN expression (Figure 6D), and the minimal alteration of cell cycle
was probably caused by the effect of DOX itself [11]. Inhibition of Akt
(Figure 6E), the major downstream target of PTEN lipid phosphatase
activity, by an Akt-specific inhibitor, Akt inhibitor VIII [22], signifi-
cantly decreased expression levels of cdc6 and cyclin E2 (Figure 6F ).
In contrast, inhibition of the JNK signaling pathway (identified as a
PTEN functional target in parallel to Akt [23]; Figure 6E) with a specific
JNK inhibitor, SP600125 [24], showed no effect on the expression of
these two genes. Collectively, these results suggest that the inhibition of
cdc6 and cyclin E2 expression by PTEN is dependent on its lipid phos-
phatase activity and is mediated through the Akt pathway.
PTEN Regulates Cdc6 Expression through the E2F
Transcription Factor in C4-2 Cells
Similar changes in the magnitude of mRNA and protein expression
of cdc6 and cyclin E2 in response to PTEN induction (Figure 3, B and
C ) suggest that these are transcriptionally regulated. Because expres-
sion levels of cdc6 and cyclin E2 can be regulated by the E2F transcrip-
tion factor [19,25], here we evaluate whether PTEN exerts its effect
on cdc6 and cyclin E2 through E2F. We examined whether PTEN
could affect E2F transcriptional regulation by examining E2F reporter
activity after PTEN expression. E2F luciferase-reporter construct was
transiently transfected into the C4-2 cells, and the expression of PTEN
inhibited E2F reporter activity approximately 40% (Figure 7A), a sim-
ilar decrease to that seen in mRNA and protein expression of cdc6
and cyclin E2, and this inhibition of E2F reporter activity was not
caused by the effect of PTEN on E2F expression levels (Figure 7A).
Surprisingly, PTEN expression had no effect on the phosphorylation
levels of Rb, a known factor that regulates E2F transcriptional ac-
tivity. To determine the role of E2F in cdc6 transcriptional regula-
tion by PTEN, we transiently transfected wild type and mutant
Figure 3. Cdc6 and cyclin E2 expression levels in human prostate cancer tumors. Cdc6 (A and C) and cyclin E2 (B and D) expression
levels in two independent human tumor array data sets. All probe sets available for each gene are shown. Data in panels A and B were
derived from study conducted by Varambally et al. [15], and data in C and D were obtained from an Oncomine study [20]. Numbers on
top of bar graph in A and B show fold difference compared to localized samples. Error bars, SEM.
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cdc6 promoter (mutations in both E2F binding sites) constructs into
C4-2 cells and examined cdc6 promoter activity after PTEN expres-
sion. Whereas wild type cdc6 promoter activity was decreased approx-
imately 35% after PTEN expression, the activity of mutant cdc6
promoter was unaffected by PTEN expression (Figure 7B). These re-
sults suggest that PTEN expression inhibits expression of cdc6
through the E2F transcription factor.
The effect of PTEN on E2F transcriptional activity prompted us
to examine whether PTEN modulates other E2F-regulated genes and
whether those genes are also associated with human prostate cancer
metastasis. We used a computational tool called PAINT [17] to un-
cover putative transcription factor–regulatory pathways associated
with gene down-regulation by PTEN. By looking at overrepresented
transcription factor binding sites in the regulatory regions of PTEN
down-regulated genes, we found that E2F was among the most sig-
nificant predications by PAINT of transcription factors regulated by
PTEN (Table 2). In the clustering analysis (Figure 7C ), PAINT iden-
tified two additional PTEN-regulated E2F genes, denticleless homo-
log (DTL) and DNA fragmentation factor (DFFB). We then
evaluated their expression levels in human prostate cancer [15].
Figure 7D indicates that levels of DFFB did not change, whereas ex-
pression levels of DTL were increased dramatically in metastatic sam-
ples compared to benign and localized samples. These results further
support the regulatory role of E2F transcription activity by PTEN
Figure 4. Expression levels of cdc6 and cyclin E2 in response to PTEN. mRNA (A) and protein (B) expression levels of cdc6 and cyclin E2
after PTEN expression. pTetOn PTEN C4-2 cells were treated with 1 μg/ml DOX for 24 hours to reexpress PTEN; total RNA and cell lysate
were extracted from duplicate samples to do real-time RT-PCR and Western blot, respectively, to determine mRNA and protein expres-
sion levels of cdc6 and cyclin E2. Graph represents densitometry analysis of cdc6 and cyclin E2 protein levels from two independent
experiments after PTEN expression with 1 μg/ml DOX treatment for 24 hours. Protein levels of cdc6 and cyclin E2 were normalized by
levels of α-tubulin (inset). (C) Western blots showing siRNA-mediated knockdown of PTEN (siPTEN) in prostate cancer DU145 cells after
72 hours of transient transfection of siRNA. (D) Corresponding cdc6 and cyclin E2mRNA expression levels after siRNA-mediated knock-
down of PTEN, in DU145 cells were determined with real-time RT-PCR. *P < .05 and **P < .01, respectively, compared to DMSO
treatment or control siRNA targeting luciferase (siGL2).
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and indicate an association of PTEN-regulated E2F genes and hu-
man prostate cancer metastasis.
Discussion
In prostate cancer, loss of PTEN has been associated with more
advanced disease and previous studies indicate that PTEN regulates
prostate cancer androgen sensitivity and bone tropism [11,26]. Using
a PTEN-deficient human prostate cancer cell line harboring an inducible
PTEN expression construct, we defined a PTEN gene expression signa-
ture.We then evaluated the association of this signaturewith tumor stage
from profiling data on human prostate cancers. Finally, by filtering genes
which are both suppressed by PTEN and elevated as a function of hu-
man tumor metastasis, we defined candidate biomarkers or effectors of
PTEN-mediated metastasis associated pathways. We found that genes
regulated by PTEN expression could clearly distinguish metastatic pros-
tate tumor samples from benign and localized prostate tumor tissues,
supporting the idea that PTEN-associated transcriptional programs are
involved in the late stages of tumor progression in prostate cancer. Al-
though we cannot rule out possible secondary effects of PTEN expres-
sion, the relatively short period of PTEN induction suggested a more
direct role of PTEN in transcriptional regulation of those genes.
Our approach is complementary to that used in two recent reports
examining the link between transcriptional signatures associated
with PTEN loss and cancer prognosis [10,27]. In contrast to our ap-
proach, these investigators first used patient material or human xeno-
grafts with characterized PTEN status to develop a gene signature.
The nine-gene signature discovered by Mehrian-Shai et al. reflected
PTEN status in a set of human glioblastoma and human prostate can-
cer xenografts. Of these nine genes, the secreted protein IGFBP-2 was
found to be a potential biomarker of PTEN status and might possibly
serve as a tool to monitor PI3K signaling in pathway-specific targeted
treatment. Similarly, stathmin was found as a surrogate marker for the
246–PTEN gene signature discovered from human breast cancer sam-
ples, and those signature genes not only reflected PTEN-associated
PI3K signaling pathway alternation but also integrated various PI3K
pathway lesions. In addition, the 246-gene signature was associated
with a significantly worse distant disease-free survival in both breast
and prostate cancer tumor samples. Interestingly, none of the signature
genes of Mehrian-Shai et al. were present among our PTEN-regulated
genes, and only one common gene was found between our data set
and that of Saal et al., PTEN itself. Similarly, there was overlap of
only one gene, TUA8 Cri-du-chat region, between Mehrian-Shai et al.
and Saal et al. The lack of overlap among signatures that predict
disease stage or recurrence is not unusual [28] and is likely caused
by the different approaches used by our study and the other two
studies. Despite this, such signatures can be robustly predictive of dis-
ease outcome [29].
The role of PTEN and related PI3K-Akt pathway in transcriptional
regulation has been explored in numerous gene expression micro-
array studies [30,31], and it would seem that multiple mechanisms
are involved. Our study indicates that regulation of cdc6 and cyclin E2
expression by PTEN is mediated through its effect on PI3K-Akt sig-
naling because the G129E mutant PTEN has no inhibition on their
expression. Expression of cyclin E2 has been related to PTEN status
Figure 5. Time course study of PTEN, cdc6, and cyclin E2 expression and cell cycle distribution. pTetOn PTEN C4-2 cells were treated
with DOX for 6, 12, and 24 hours to induce PTEN expression. (A) The expression of PTEN was determined by Western blot with an anti-
HA antibody. (B) Correlated cell cycle distribution was determined by propidium iodide staining as described in Materials and Methods
with a duplicate sample. (C) Total RNA from a triplicate sample was isolated to examine cdc6 and cyclin E2 mRNA levels by real-time
RT-PCR. Error bars, SEM. *P < .05 and **P < .01, respectively, compared to 0 time point.
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because elevated cyclin E2 levels were observed in epidermal sites after
conditional PTEN ablation [32]. Our work demonstrates a causal
linkage and further indicates that the regulation of cdc6 expression
by PTEN is mediated through the E2F transcriptional factor. E2F
is involved in the regulation of multiple genes that are essential to cell
cycle G1-to-S transition including cdc6 and cyclin E2 [19,25], and our
results suggest that PTEN could affect E2F transcription activity. E2F
activity is inhibited on binding to hypophosphorylated Rb [33] whose
phosphorylation is inhibited by PTEN, and this inhibition is rescued
by the expression of a catalytically active subunit of PI3K [34]. How-
ever, PTEN expression did not change phosphorylation levels of
Rb in our C4-2 cells suggesting that Rb was not involved in PTEN
inhibition of E2F activity here. Alternatively, PTEN might directly
affect E2F function because Shen et al. [35] reported that PTEN inter-
acted with E2F to influence the transcriptional regulation of Rad51.
Recently, inhibition of the PI3K-Akt downstream target, GSK-3β, by
either inhibitor or siRNA treatment decreased cdc6 and cyclin E2 ex-
pression, and this inhibition was suggested to be mediated through
E2F in prostate cancer cells [36]. Together with our results, these
studies suggest potential roles of PI3K-Akt and E2F in the regulation
of cdc6 and cyclin E2 expression by PTEN.
The cell cycle G1 arrest by PTEN has been reported previously [37],
and we observed similar result in C4-2 cells [11]. Cdc6 is involved in
cell cycle G1-to-S transition and siRNA knockdown of cdc6 expression
caused cancer cell G1 arrest and apoptosis because it is essential to
DNA replication [38]. Similarly, cyclin E2 has been associated with
cell cycle G1- to S-phase transition by associating and activating of
CDK2, and its overexpression decreased cell cycle G1 length [21].
Our studies here show a significant decrease of cdc6 and cyclin E2
expression before the cell cycle G1 arrest, suggesting that the inhibition
of these two genes by PTEN is not simply caused by the global inhi-
bition of PTEN cell cycle G1 arrest. Rather, the inhibition of cdc6
and cyclin E2 by PTEN could be involved in its cell cycle G1 arrest
function given the essential roles of these two genes in cell cycle G1-
to S-phase transition.
It should be noted that the cell cycle arrest in C4-2 cells after PTEN
restoration could potentially skew our PTEN-regulated metastasis-
associated gene lists toward cell cycle–regulatory genes that impact
metastasis by regulating growth at the distant site. Thus, other gene
families that regulate metastasis may not have been identified as easily
if overshadowed by these growth-related genes. Further direct evidence
would be needed to determine directly whether these cell cycle–
regulatory genes are actually involved in the metastatic colonization
process [39]. Nevertheless, there is significant evidence that cdc6 and
cyclin E2 are associated with progression in human cancer. For exam-
ple, enhanced expression of cdc6 was found in metastatic melanomas,
and increased expression in primary melanomas was associated with
bad prognosis [40]. The expression level of cyclin E2 was increased
and associated with decreased metastasis-free survival and overall sur-
vival in breast cancer [41]. Our results implicating increased expression
of cdc6 and cyclin E2 in humanmetastatic prostate cancer tissues in two
microarray studies from independent centers [15,20] are consistent
Figure 6. Role of PTEN lipid phosphatase activity in cdc6 and cyclin E2 expression. (A) Western blot characterization of wild type and
G129E mutant PTEN reexpression in pTetOn PTEN and pTetOn PTEN (G129E) C4-2 cells after 1 μg/ml DOX treatment for 24 hours. Cdc6
(B) and cyclin E2 (C) expression levels were determined by real-time RT-PCR after wild type (wt) or G129E mutant PTEN expression. (D)
Correlated cell cycle distribution was determined by propidium iodide staining as described in Materials and Methods with a duplicate
sample. (E) Western blots showing inhibition of phospho-Akt (pAkt) with 5 μMAkt inhibitor (Akti), Akt inhibitor VIII, and decreased phospho-
c-Jun levels with 10 μM JNK inhibitor (JNKi), SP600125, in pTetOnPTEN C4-2 cells after 24 hours of treatment. (F) Total RNA in C4-2 cells
treated with Akt and JNK inhibitors in (E) was extracted to determine mRNA levels of cdc6 and cyclin E2 by real-time RT-PCR. Error bars,
SEM. *P < .05 and **P < .01, respectively, compared to control (no DOX or DMSO treatment).
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with these studies. Future IHC studies in metastatic prostate cancer
tissues need to be carried out to determine whether protein levels of
cdc6 and cyclin E2 are correlated to their mRNA levels in metastatic
samples. Given our data, such correlation is likely.
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Figure 7. Effects of PTEN expression on E2F transcriptional activity and cdc6 promoter activity. (A) E2F reporter luciferase construct was
transiently transfected into pTetOn PTEN C4-2 cells. Cells were treated with 1 μg/ml DOX for 24 hours, and E2F reporter activity was
measured by luciferase assay. Inset: Western blots showing expression levels of E2F-1 and phosphor-Rb (S780) after PTEN expression.
(B) Wild type (wt) or mutant (DM, double mutation on both E2F binding sites) cdc6 promoter-luciferase construct was transiently trans-
fected into pTetOn PTEN C4-2 cells. Cdc6 promoter activity was determined by luciferase assay after PTEN expression in cells treated
with 1 μg/ml DOX for 24 hours. The luciferase activity of DOX treatment was normalized to no DOX in both wild type and mutant groups.
(C) PAINT clustering analysis showing interaction matrix for statistically overrepresented transcriptional regulatory elements (TREs) in
PTEN down-regulated genes. The corresponding PTEN down-regulated genes whose upstream sequences harbor those TREs were
listed in the column next to the matrix. (D) Relative expression levels of probe sets representing DTL and DFFB in human prostate tumor
array data [15]. All probe sets available for each gene were shown. Data indicate fold change difference compared to benign. Error bars,
SEM. *P < .05 and **P < .01, respectively, compared to no DOX treatment.











†P values were calculated by PAINT Web service (http://www.dbi.tju.edu/dbi/tools/paint/).
*Multiple listings of same transcriptional factors are based on differences in consensus binding sites.
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